Press Release

Printer Friendly Version View printer-friendly version
<< Back

Histogenics Corporation to Present at Upcoming Investor Conferences


WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming healthcare investor conferences. 

  • Canaccord Genuity 11th Annual Musculoskeletal ConferenceOrlando, FL (March 1, 2016)

    Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Tuesday, March 1, 2016, at 3:00 pm EST.   The conference immediately precedes the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting and explores the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.

  • Cowen and Company 36th Annual Health Care ConferenceBoston, MA (March 7-9, 2016)

    Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Monday, March 7, 2016, at 4:00 pm EST.

The live webcasts may be accessed by visiting the Investor Relations section of Histogenics’ website at  The webcasts will be available on Histogenics’ website for approximately 45 days following the respective conferences.

About Histogenics Corporation

Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace.  Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions.  Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development.  NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells.  Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options.  For more information, please visit


Investor Relations
Tel: +1 (781) 547-7909

Primary Logo

Histogenics Corporation